Lars Fruergaard Jørgensen, Novo Nordisk CEO (Photographer: Christopher Goodney/Bloomberg via Getty Images)
Most doses of Novo Nordisk's Ozempic are removed from FDA drug shortage list after supply issues
Novo Nordisk’s type 2 diabetes treatment Ozempic, which is also used off-label for weight loss, is back in stock following a months-long shortage, according to the FDA’s drug shortages list.
The FDA updated its website on Friday to show that Ozempic’s 0.25 mg, 0.5 mg and 1 mg doses are now available across the US. The 0.25 mg and 0.5 mg doses suffered limited supply for the last few months, according to a Novo Nordisk spokesperson. However, the 2 mg dose has “limited availability and may not fully meet demand until the end of this month,” the company told Endpoints News on Monday.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters